Additionally, the correlation between BCMA and CD47 is 0.15, indicating no significant correlation (Fig. 1B), which supports the potential of a BCMA/CD47-targeting therapeutic strategy for multiple myeloma. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.